Near-thorough QT study as part of a first-in-man study.

  title={Near-thorough QT study as part of a first-in-man study.},
  author={Marek Malik and Katerina Hnatkova and John S Ford and David Madge},
  journal={Journal of clinical pharmacology},
  volume={48 10},
Detailed electrocardiographic (ECG) support was provided to a first-in-man, single-ascending-dose study that included 6 cohorts of 8 male volunteers each. In each cohort, 6 and 2 subjects received active compound and placebo, respectively. Long-term 12-lead ECGs were obtained on baseline day -1, dosing day 1, and day 2. Automatic QT-interval measurements were made at 63 time points (28 at baseline and 35 on treatment). Based on QT/RR distribution, 20% of measurements were visually verified… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 16 extracted citations

Scientific white paper on concentration-QTc modeling

Journal of Pharmacokinetics and Pharmacodynamics • 2017
View 1 Excerpt

Moxifloxacin versus placebo modeling of the QT interval

Journal of Pharmacokinetics and Pharmacodynamics • 2012
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 23 references

Randomized , double - blind , crossover study to investigate the effect of rivaroxaban on QT - interval prolongation

BK Malhotra, P Glue, +3 authors P Wicker
Drug Saf • 2008

ICH E 14 Clinical evaluation of QT / QTc interval prolongation and proarrhythmic potential for non - antiarrhythmic drugs : guidance to industry

M Natekar, V Mahajan, A Satra, M O’Kelly, DR Karnad
Fed Regist • 2005

Similar Papers

Loading similar papers…